Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ACH Foam Technologies Reveals New Cold Chain Shipping Solution | Contract Pharma

ACH Foam Technologies Reveals New Cold Chain Shipping Solution

DuraTherm PLUS+™ will be produced in five of their eight plants across the U.S.

ACH Foam Technologies has revealed their newest product, DuraTherm PLUS+™. It’s a cold chain shipping solution that assures temperatures remain between 2 degrees to 8 degrees Celsius for a 24-hour delivery window. 

 

Validated to International Safe Transit Association (ISTA) 7D standards, it is available in both summer and winter profiles to accommodate off-the-shelf seasonal solutions for products that are temperature sensitive. ISTA’s validation assures that product temperatures can be controlled within the very narrow range for up to one day. 

 

“The ISTA’s validation of DuraTherm PLUS+™sets a high benchmark and will provide customers great confidence in their product’s protection during shipment,” says Frank Kiesecker, senior vice president of Sales & Marketing at ACH Foam Technologies. 

 

ACH Foam says the key of DuraTherm PLUS+™’s ability to maintain near-constant temperatures is the expanded polystyrene (EPS) foam cooler core, which boasts superior insulation properties. 


The product is available in four different sizes, and will be produced in five of their eight plants across the United States, allowing for cost-effective shipping to any U.S. location.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters